Next Article in Journal
Predictors of Noninvasive Ventilation Failure in Critically Ill Obese Patients: A Brief Narrative Review
Previous Article in Journal
Pulmonary Function Tests Leading to the Diagnosis of Vascular Malformations in School-Aged Children
 
 
Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Sarcoidosis-Associated Pulmonary Hypertension Treated with Sildenafil

by
Aneta Kacprzak
1,*,
Monika Szturmowicz
1,
Barbara Burakowska
2,
Monika Franczuk
3,
Jarosław Kober
2,
Marcin Kurzyna
4,
Michał Wilk
5,
Sebastian Szmit
4,
Adam Torbicki
4 and
Jan Kuś
1
1
1st Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
2
Department of Radiology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
3
Department of Respiratory Physiopathology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
4
Department of Cardiovascular and Pulmonary Thromboembolic Diseases CMKP, European Health Centre Otwock, Otwock, Poland
5
Oncology Department, European Health Centre Otwock, Otwock, Poland
*
Author to whom correspondence should be addressed.
Adv. Respir. Med. 2017, 85(5), 258-263; https://doi.org/10.5603/ARM.a2017.0043
Submission received: 11 July 2017 / Revised: 23 September 2017 / Accepted: 23 September 2017 / Published: 30 October 2017

Abstract

Development of sarcoidosis-associated pulmonary hypertension (SAPH) significantly worsens prognosis in sarcoidosis patients. Unfortunately, there is no treatment of proven benefit for this condition. Medications used for treatment of pulmonary arterial hypertension are of great interest in this respect. Here, we report a case of a patient with severe SAPH treated with sildenafil. A significant, but only temporary improvement in functional status was observed, and the patient died of gradually progressing heart and respiratory failure while awaiting for lung transplantation.
Keywords: sarcoidosis; pulmonary hypertension; treatment; sidlenafil sarcoidosis; pulmonary hypertension; treatment; sidlenafil

Share and Cite

MDPI and ACS Style

Kacprzak, A.; Szturmowicz, M.; Burakowska, B.; Franczuk, M.; Kober, J.; Kurzyna, M.; Wilk, M.; Szmit, S.; Torbicki, A.; Kuś, J. Sarcoidosis-Associated Pulmonary Hypertension Treated with Sildenafil. Adv. Respir. Med. 2017, 85, 258-263. https://doi.org/10.5603/ARM.a2017.0043

AMA Style

Kacprzak A, Szturmowicz M, Burakowska B, Franczuk M, Kober J, Kurzyna M, Wilk M, Szmit S, Torbicki A, Kuś J. Sarcoidosis-Associated Pulmonary Hypertension Treated with Sildenafil. Advances in Respiratory Medicine. 2017; 85(5):258-263. https://doi.org/10.5603/ARM.a2017.0043

Chicago/Turabian Style

Kacprzak, Aneta, Monika Szturmowicz, Barbara Burakowska, Monika Franczuk, Jarosław Kober, Marcin Kurzyna, Michał Wilk, Sebastian Szmit, Adam Torbicki, and Jan Kuś. 2017. "Sarcoidosis-Associated Pulmonary Hypertension Treated with Sildenafil" Advances in Respiratory Medicine 85, no. 5: 258-263. https://doi.org/10.5603/ARM.a2017.0043

Article Metrics

Back to TopTop